Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer
Dongbing Zhao, Pinli Yue, Tongbo Wang, Pei Wang, Qianqian Song, Jingjing Wang, Yuchen Jiao, Dongbing Zhao, Pinli Yue, Tongbo Wang, Pei Wang, Qianqian Song, Jingjing Wang, Yuchen Jiao
Abstract
Peritoneal dissemination (PD) is a major type of gastric cancer (GC) recurrence and leads to rapid death. Current approaches cannot precisely determine which patients are at high risk of PD to provide early intervention. In this study, we developed a technology to detect minimal residual cancer cells in peritoneal lavage fluid (PLF) samples with a personalized assay profiling tumor-specific mutations. In a prospective cohort of 104 GC patients, the technology detected all the cases that developed PD with 100% sensitivity and 85% specificity. The minimal residual cancer cells in PLF were associated with a significantly increased risk of PD (HR = 145.13; 95% CI 20.20-18,435.79; p < 0.001), which was the strongest independent predictor over pathologic diagnosis and cytological diagnosis. In pathologically high-risk (pT4) patients, the PLF mutation profiling model exhibited a greater specificity of 91% and a positive predictive value of 88% while retaining a sensitivity of 100%. This approach may help in the postsurgical management of GC patients by detecting PD far before metastatic lesions grow to a significant size detectable by conventional methods such as MRI and CT scanning.
Keywords: Gastric cancer; Minimal residual disease; Peritoneal dissemination; Peritoneal lavage fluid; Personalized mutation assay.
Conflict of interest statement
Yuchen Jiao, Dongbing Zhao, Pei Wang, Qianqian Song and Pinli Yue have filed patents/patent applications based on the technology and data generated from this work. Yuchen Jiao is one of the cofounders, has owner interest in Genetron Holdings, and receives royalties from Genetron. The remaining authors disclose no conflicts.
© 2021. The Author(s).
Figures
References
- Badgwell B, Roy-Chowdhuri S, Chiang YJ, Matamoros A, Blum M, Fournier K, et al. Long-term survival in patients with metastatic gastric and gastroesophageal cancer treated with surgery. J Surg Oncol. 2015;111(7):875–881. doi: 10.1002/jso.23907.
- Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, et al. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134(3):622–628. doi: 10.1002/ijc.28373.
- Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, et al. The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer. 2017;79:1–14. doi: 10.1016/j.ejca.2017.03.030.
- Lei Z, Wang J, Li Z, Li B, Luo J, Wang X, et al. Hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: a multicenter propensity score-matched cohort study. Chin J Cancer Res. 2020;32(6):794–803. doi: 10.21147/j.issn.1000-9604.2020.06.12.
- Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028–2040. doi: 10.1200/JCO.18.01688.
- Coombes RC, Page K, Salari R, Hastings RK, Armstrong A, Ahmed S, et al. Personalized detection of circulating tumor DNA antedates breast cancer metastatic recurrence. Clin Cancer Res. 2019;25(14):4255–4263. doi: 10.1158/1078-0432.CCR-18-3663.
- Reinert T, Henriksen TV, Christensen E, Sharma S, Salari R, Sethi H, et al. Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages i to iii colorectal cancer. JAMA Oncol. 2019;5(8):1124–1131. doi: 10.1001/jamaoncol.2019.0528.
- Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451. doi: 10.1038/nature22364.
- McDonald BR, Contente-Cuomo T, Sammut SJ, Odenheimer-Bergman A, Ernst B, Perdigones N, et al. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Sci Transl Med. 2019 doi: 10.1126/scitranslmed.aax7392.
- Azad TD, Chaudhuri AA, Fang P, Qiao Y, Esfahani MS, Chabon JJ, et al. Circulating tumor DNA analysis for detection of minimal residual disease after chemoradiotherapy for localized esophageal cancer. Gastroenterology. 2020;158(3):494–505.e6. doi: 10.1053/j.gastro.2019.10.039.
Source: PubMed